240 related articles for article (PubMed ID: 14635208)
1. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
Liu LG; Tanaka H; Ito K; Kyo T; Ito T; Kimura A
Am J Hematol; 2003 Dec; 74(4):268-72. PubMed ID: 14635208
[TBL] [Abstract][Full Text] [Related]
2. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2.
Iwata S; Mizutani S; Nakazawa S; Yata J
Leukemia; 1994 Oct; 8(10):1696-702. PubMed ID: 7934165
[TBL] [Abstract][Full Text] [Related]
4. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
Martinelli G; Terragna C; Amabile M; Montefusco V; Testoni N; Ottaviani E; de Vivo A; Mianulli A; Saglio G; Tura S
Haematologica; 2000 Jan; 85(1):40-6. PubMed ID: 10629590
[TBL] [Abstract][Full Text] [Related]
5. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
Sugimoto T; Ijima K; Hisatomi H; Murayama T; Mizuno I; Hato A; Imoto S; Nishimura R; Koizumi T
Am J Hematol; 2004 Oct; 77(2):164-6. PubMed ID: 15389825
[TBL] [Abstract][Full Text] [Related]
6. [Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].
Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Shi HL; Qiu JY; Lu DP; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):409-12. PubMed ID: 15355693
[TBL] [Abstract][Full Text] [Related]
7. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
Prejzner W
Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
[TBL] [Abstract][Full Text] [Related]
8. An atypical (b3/a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia.
Amabile M; Martinelli G; Terragna C; Montefusco V; Tabilio A; Tura S
Haematologica; 1999 Jun; 84(6):573-5. PubMed ID: 10366813
[No Abstract] [Full Text] [Related]
9. A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.
Sadia H; Siddiqui RT; Nasim A
Cancer Genet Cytogenet; 2010 Aug; 201(1):57-61. PubMed ID: 20633771
[TBL] [Abstract][Full Text] [Related]
10. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
11. Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Martinelli G; Amabile M; Giannini B; Terragna C; Ottaviani E; Soverini S; Saglio G; Rosti G; Baccarani M
Haematologica; 2002 Jul; 87(7):688-94; discussion 694. PubMed ID: 12091118
[TBL] [Abstract][Full Text] [Related]
12. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
15. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
18. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
19. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons.
How GF; Lim LC; Kulkarni S; Tan LT; Tan P; Cross NC
Br J Haematol; 1999 May; 105(2):434-6. PubMed ID: 10233416
[TBL] [Abstract][Full Text] [Related]
20. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
